K.H. Lee

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)

Min‐Hee Ryu, Eishi Baba, K.H. Lee et al. · Annals of Oncology · 2015 · 47 citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

Kenneth J. O’Byrne, K.H. Lee, S.-W. Kim et al. · ESMO Open · 2022 · 21 citations · Full text

Randomized Phase Ii Study of Capecitabine and Cisplatin with or Without Sorafenib in Patients with Metastatic Gastric Cancer: Stargate Study

Yoon‐Koo Kang, K.H. Lee, Lin Shen et al. · Annals of Oncology · 2014 · 17 citations

Gastrointestinal Oncology, Medicine, Pharmacology +8

Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

Tony Mok, Ying Cheng, Xiangdong Zhou et al. · Annals of Oncology · 2019 · 14 citations · Full text

Health Sciences, Overall Survival, Medicine +10

Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)

Luis Paz‐Ares, E.H. Tan, L. Zhang et al. · Annals of Oncology · 2016 · 13 citations · Full text

Non-small-cell Lung Cancer, Overall Survival, Medicine +8